XORTX Therapeutics: Pioneering New Therapies for Progressive Kidney Disease

XORTX is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADP …

March 1, 2022
Request Investor InfoRequest Investor Info

Redefining Kidney Disease Through Strategic Collaborations

XORTX is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection as well as XRx-225 which is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, they are dedicated to developing medications to improve the quality of life and future health of patients.

For more information on XORTX Therapeutics Inc. (TSX.V: XRTX) please click the request investor info button.

Investing
stock market

You might also like

Equiton: An Expert Approach to Alternative Investments
Finance
January 16, 2026

Equiton: An Expert Approach to Alternative Investments

Advisors looking to diversify client portfolios with alternatives turn to Private Canadian Apartments^ – an asset class, which has historically performed positively across varying market cycles*.

This is some text inside of a div block.
Moon River Moly: Advancing Canada's Strategic Molybdenum Supply
Metals & Mining
January 16, 2026

Moon River Moly: Advancing Canada's Strategic Molybdenum Supply

Moon River Moly is advancing two of Canada’s most promising molybdenum projects to meet growing global demand.

This is some text inside of a div block.
Invest Better with BMO ETFs: Canada’s Homegrown Leader in Innovation
ETFs
January 15, 2026

Invest Better with BMO ETFs: Canada’s Homegrown Leader in Innovation

For over 16 years, BMO ETFs has stood out as a trailblazer in the Canadian investment space, managing over $160 billion in assets and offering solutions designed by Canadians, for Canadians

This is some text inside of a div block.
Subscribe and receive the investor Info